Introduction
Cyclooxygenases are key enzymes in the prostaglandin synthesis. The inducible isoenzyme cyclooxygenase-2 (COX-2) plays a pivotal role as a mediator of inflammation. In addition, COX-2 expression is associated with carcinogenesis most likely by modulating apoptosis (Dannenberg et al., 2001) . With regard to its latter function, COX-2 was shown to be upregulated in a variety of human cancers including colon, gastric, esophagus, pancreas and breast cancer, while undetectable in most normal tissues (Eberhart et al., 1994; Subbaramaiah et al., 1996; Ristima¨ki et al., 1997; Hida et al., 1998; Tucker et al., 1999; Zimmerman et al., 1999) . Furthermore, overexpression of COX-2 was sufficient to cause tumorigenesis in animal models and to render cells resistant to apoptotic stimuli Lin et al., 2001; Cao and Prescott, 2002) . Supporting evidence for a crucial role of COX-2 in cell survival was also provided by Oshima et al. (1996) , who demonstrated that knocking out the COX-2 gene in a genetically driven mouse model of intestinal carcinogenesis resulted in substantial reduction in the number and size of intestinal polyps. Together, these findings suggested that inhibition of the COX-2 activity, and hence the resulting decrease in prostaglandin production may contribute to the well-documented anticancer effect of nonsteroidal anti-inflammatory drugs (NSAIDs) (Taketo, 1998; Gupta and DuBois, 2000; Thun et al., 2002) . Indeed, selective COX-2 inhibitors have been demonstrated to modulate tumorigenic, angiogenic and apoptotic events resulting in reduction of tumor incidence and progression (Cao and Prescott, 2002) . The specific COX-2 inhibitor NS-398, for example, was shown to suppress tumor growth of different cancer cell lines and to induce apoptosis in human colon carcinoma, prostate carcinoma and esophageal adenocarcinoma cells (Liu et al., 1998; Smith et al., 2000; Souza et al., 2000) . Other specific COX-2 inhibitors such as nimesulide and celecoxib induced apoptosis in nonsmall lung cancer, prostate carcinoma, as well as colon cancer cells (Hida et al., 2000; Hsu et al., 2000; Gro¨sch et al., 2001) , and efficiently inhibited tumor growth in animal models, respectively (Masferrer et al., 2000) . COX-2 is therefore considered as an attractive target for the treatment of cancer.
Although a clinical significance of COX-2 inhibitors is well established, the mechanism of the chemopreventive action used by these compounds is largely unknown. Indeed, there is accumulating evidence suggesting that the antineoplastic effect of NSAIDs may not solely be mediated by the inhibition of COX-2 activity and a subsequent decrease of prostaglandin E 2 (PGE 2 ) synthesis, but by other cellular targets besides COX-2. This assumption is largely based on the observation that significantly higher concentrations of NSAIDs are necessary to inhibit cell growth and to induce apoptosis than those required for the inhibition of prostaglandin production . Furthermore, NSAIDs reduced cell survival not only in COX-2-expressing cells, but also in COX-2-deficient cell lines (Elder et al., 1997; Zhang et al., 1999; Gro¨sch et al., 2001) . As COX-2 inhibitors such as celecoxib and nimesulide are already in use in several clinical trials, it will be tremendously important to decipher and understand the pathways that underlie the apoptosispromoting activities of these compounds.
In our continuous effort to define mechanisms leading to apoptosis resistance, we carried out a suppression subtractive hybridization approach using a pair of HeLa cell lines that exhibit different TNF susceptibilities (Ja¨nicke et al., 1994 (Ja¨nicke et al., , 1996 . Among several genes identified, we found the COX-2 gene to be differentially expressed in the two HeLa cell lines, providing a cellular model system to investigate the effect of COX-2 and specific COX-2 inhibitors on apoptosis induced by various death stimuli. Here we demonstrate that the two selective COX-2 inhibitors NS-398 and nimesulide, even at nontoxic concentrations, strongly sensitize tumor cells to TNF and overcome apoptosis resistance. Interestingly, the apoptosispromoting effect of COX-2 inhibitors was specifically observed in response to activation of death receptors, while apoptosis induced by anticancer drugs that target the mitochondrial pathway remained unaffected. Our data also indicate that COX-2 inhibitors might induce apoptosis by cellular targets that are not necessarily related to inhibition of prostaglandin synthesis. Taken together, our findings provide new insights into the molecular mechanisms of NSAID-induced apoptosis and may be useful in designing novel death receptor-based therapeutic strategies for the treatment of cancer.
Results

Expression and activity of COX-2 correlate with TNF sensitivity
In order to identify proteins involved in the modulation of apoptosis, we employed the suppression subtractive hybridization method with mRNA from TNF-resistant (H21) and TNF-sensitive (D98) HeLa cell lines (Ja¨nicke et al., 1994 (Ja¨nicke et al., , 1996 that were treated for 1 h with a combination of TNF and cycloheximide. Using this approach, we identified the COX-2 gene as being differentially expressed in the two HeLa cell lines. The overexpression of COX-2 in TNF-resistant HeLa H21 cells was confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR) (Figure 1a) , a finding that is in agreement with several reports demonstrating a crucial role for this enzyme in cell survival McGinty et al., 2000; Lin et al., 2001) . TNF treatment efficiently induced COX-2 mRNA and protein expression in both cell lines in a time-dependent manner; however, a much stronger induction as judged by the actin control was consistently observed in HeLa H21 cells (Figure 1b and c) .
To examine whether COX-2 protein expression correlates with its enzymatic activity, the PGE 2 levels were determined in HeLa H21 and D98 cells treated with TNF in the absence or presence of the selective COX-2 inhibitor NS-398. As expected, a dramatic increase in the PGE 2 concentration was detected in H21 cells 3, 6 and 12 h after exposure to TNF which was completely abolished by NS-398 (Figure 1d, left panel) . Surprising, however, was our finding that despite an Figure 1 COX-2 is differentially expressed and activated in TNFresistant HeLa H21 and TNF-sensitive D98 cells. (a) To verify the results obtained by the SSH procedure, total RNA from HeLa H21 and D98 cells that were exposed for 1 h to a combination of TNF (100 pg/ml) and cycloheximide (10 mg/ml) was subjected to RT-PCR using COX-2-specific primers (upper panel (Figure 2a and data not shown). Death of D98 cells was induced by TNF in a dose-and time-dependent manner and was even further enhanced when the cells were treated with a combination of TNF and NS-398 ( Figure 2a ). Similar results were obtained when another COX-2-specific inhibitor, nimesulide, was used ( Figure 2b ). Furthermore, TNF treatment resulted in a significant activation of caspase-3, which was further increased when the cells were treated with the combination of TNF and nimesulide (data not shown). As caspase-3 is required for DNA fragmentation and other classical hallmarks of apoptosis (Ja¨nicke et al., 1998; Porter and Ja¨nicke, 1999) , our data show that the COX-2 inhibitors used exert an apoptosis-promoting activity. Importantly, COX-2 inhibitors could overcome apoptosis resistance at concentrations that were not toxic on their own. The apoptosis-promoting activity of the COX-2 inhibitors was even more pronounced in HeLa D98 cells (Figure 2 ), a cell line that lacks COX-2 activity. We therefore sought to investigate the specificity of the COX-2 inhibitors and assessed the effect of various doses of NS-398 in combination with TNF on cell death and PGE 2 synthesis in H21 cells. This approach enabled us to compare directly the inhibitor concentrations required for cell death induction and suppression of COX-2 activity. TNF-induced PGE 2 production was already diminished by approximately 50% and even completely abolished using NS-398 concentrations as low as 1 and 10 nm, respectively (Figure 3a) . In contrast, only the highest concentration of NS-398 (100 mm) was able to induce significantly death of H21 cells when combined with TNF, whereas lower NS-398 concentrations of 10 and 1 mm had no effect ( Figure 3b ). Similar results were also obtained with nimesulide or when HeLa D98 cells were treated with the two inhibitors (data not shown). Thus, TNF-induced COX-2 activity in HeLa H21 cells could be inhibited by NS-398 concentrations that were 10 000-fold lower compared to those required for the induction of cell death.
To obtain more direct evidence that NS-398 functions independently of the COX-2-induced PGE 2 production, we examined the effect of different doses of this prostaglandin on TNF-and NS-398-induced death of H21 cells. As shown in Figure 3c , exogenously added PGE 2 in a concentration range of 0.1-10 mm could not reverse the death-promoting activity of TNF and NS-398 (100 mm) even after 96 h. Addition of PGE 2 also had no effect on TNF/NS-398-induced apoptosis at earlier time points (24-72 h) (data not shown). Consistent with our results shown in Figure 3b , NS-398 enhanced TNFinduced apoptosis only at 100 mm, whereas neither lower NS-398 concentrations ranging from 0.001 to 10 mm nor 
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Figure 2 COX-2 inhibitors increase TNF susceptibility of both HeLa cell lines independently of COX-2 activity. Cell death determination of HeLa H21 and D98 cells that were exposed for 24 h (left panels) and 48 h (right panels) to the indicated concentrations of TNF in the absence or presence of NS-398 (a) or nimesulide (b), respectively. As a control, cells were also treated with either inhibitor alone COX-2 inhibitors enhance death receptor-triggered apoptosis G Totzke et al the additional application of PGE 2 had any effect after 24-96 h (data not shown). These data demonstrate that apoptosis induction and inhibition of COX-2 activity can be dissociated by the pharmacological profile and suggest that the cytotoxic effect of NS-398 is presumably independent of the inhibition of PGE 2 synthesis in TNFtreated HeLa H21 cells.
COX-2 inhibitors promote apoptosis of MCF-7 cells independently of the COX-2 status
Although our results so far suggest that COX-2 is not involved in TNF resistance, at least in HeLa H21 cells, due to the lack of COX-2 activity in D98 cells, we cannot unambiguously rule out a role for the enzyme in this cell line. To investigate the effect of the COX-2 inhibitors also in another cell system, we performed experiments in MCF-7/casp-3 cells. MCF-7/casp-3 cells were chosen because they do not express COX-2 ( Figure 4a ) and because we could not rule out the possible existence of a natural COX-2 inhibitor that might be present in HeLa D98 cells. In order to obtain more direct evidence whether COX-2 could alter cellular sensitivity to apoptosis, MCF-7/casp-3 cells were stably transfected with an expression plasmid containing the COX-2 cDNA or as a control with the empty vector. Western blot analysis confirmed that the vector-transfected control cells (pcDNA4) do not express COX-2 protein, whereas several zeocinselected clones exhibited a strong COX-2 expression ( Figure 4a ). The positive COX-2 clones and the vector control cells were then treated with TNF and analysed for their PGE 2 production and cell death induction. As expected, in control vector cells that do not express COX-2, TNF was not able to induce PGE 2 synthesis, but, surprisingly, also COX-2-overexpressing cells did not display any significant enzyme activity ( Figure 4b ). In addition, cell death determinations revealed that the COX-2-overexpressing MCF-7/casp-3 clones and the control vector cells were almost identical in their response to TNF (Figure 4c ). However, in agreement with our results shown in Figure 2 , the COX-2 inhibitor nimesulide enhanced TNF sensitivity of vector and COX-2-expressing clones to the same extent, despite the lack of detectable COX-2 activity. Similar results were also obtained with the other MCF-7/casp-3 clones stably expressing COX-2 (data not shown) demonstrating that the proapoptotic activity of COX-2 inhibitors is mediated via a COX-2-independent pathway. Cell death determination of HeLa H21 cells that were treated for 96 h with either TNF or NS-398 alone or with a combination of both in the absence or presence of the indicated PGE 2 concentrations COX-2 inhibitors enhance death receptor-triggered apoptosis G Totzke et al
COX-2 inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis
Apoptosis can be mediated via two principal signaling pathways: the extrinsic or death receptor pathway and the intrinsic or mitochondrial death pathway (SchulzeOsthoff et al., 1998; Daniel et al., 2001) . As TNF instigates apoptosis via the extrinsic pathway, we asked whether COX-2 inhibitors can also enhance apoptosis induced by other death receptor ligands such as the anti-CD95 mAb or the TNF-related apoptosis-inducing ligand (TRAIL). Experiments with TRAIL were performed in particular, because this death ligand is currently regarded as a promising biological agent in cancer therapy (Walczak and Krammer, 2000; Held and Schulze-Osthoff, 2001) . For this purpose, we first analysed the effect of these death receptor ligands on COX-2 expression and activity. Although COX-2 mRNA and protein expression in both HeLa cell lines were significantly induced by TNF, treatment of the cells with either anti-CD95 mAb or TRAIL had only marginal effects (Figures 1 and 5) . PGE 2 production, and hence COX-2 activity, was also dramatically increased only in TNF-treated H21 cells, but could not be induced in both HeLa cell lines with either the anti-CD95 mAb or TRAIL (Figure 5c ). However, despite the fact that only TNF was able to induce COX-2 expression and activity (at least in H21 cells), apoptosis induced by anti-CD95 mAb or TRAIL was dramatically enhanced in both cell lines in the presence of nimesulide ( Figure 6 ). Next we performed similar experiments using death stimuli that are known to activate the intrinsic mitochondrial death pathway such as etoposide and doxorubicin (Wesselborg et al., 1999; Engels et al., 2000) . Although both death stimuli slightly increased COX-2 mRNA (Figure 7a ) and protein (Figure 7b ) expression, at least in HeLa D98 cells, they could not induce PGE 2 production in either of the cell lines (Figure 7c ). More importantly, however, was the finding that nimesulide had no effect on apoptosis induced by etoposide or doxorubicin (Figure 8 ). Both HeLa cell lines were killed to the same extent by these drugs in the absence or presence of the COX-2 inhibitor. Together, these data provide strong evidence that the COX-2 inhibitors used in this study exert their proapoptotic function independently of their ability to suppress COX-2 activity, and moreover indicate that they specifically target the death receptor pathway.
Discussion
Using the suppression subtractive hybridization (SSH) technique, we identified the COX-2 gene as being differentially expressed in a pair of HeLa cell lines that exhibit different susceptibilities to the cytotoxic activity of TNF. COX-2 is involved in several pathological processes such as inflammation and cancer, and inhibition of apoptosis is regarded as one mechanism by which COX-2 contributes to tumorigenesis (Dempke et al., 2001) . In this respect, it was reported that COX-2 overexpression prevented apoptosis induced by nerve growth factor withdrawal in PC12 cells . Also a human lung adenocarcinoma cell line stably transfected with COX-2 showed a remarkable apoptosis resistance to UVB irradiation or vinblastine (Lin et al., 2001) . Together with our observation that TNF consistently induced a much stronger COX-2 protein expression in TNF-resistant HeLa H21 cells compared to the TNF-sensitive HeLa D98 cell line, these reports prompted us to investigate the involvement of COX-2 in cell survival.
Whether COX-2 plays a role in cell survival of HeLa D98 or MCF-7/casp-3 cells could not be unambiguously determined because TNF failed to induce significant COX-2 activity as judged by PGE 2 synthesis in both cell lines despite TNF-induced COX-2 expression or overexpression of COX-2, respectively. This phenomenon that might be due to either the presence of an inhibitory factor or the absence of an COX-2 coactivator is not restricted to the two cell lines used in the present study. COX-2 protein expression also did not correlate with COX-2 activity in the human colorectal carcinoma cell line HT-29 (Hsi et al., 2000) . As our results demonstrate that COX-2 expression is not necessarily accompanied by COX-2 activity, several studies claiming a role of COX-2 in apoptosis resistance without measuring COX-2 enzymatic activity (Hida et al., 2000; Souza et al., 2000) should be interpreted with caution.
Interestingly, we found that COX-2 inhibitors strongly potentiate apoptosis induction and that the apoptosis-promoting effect is not associated with the COX-2 status at least in the cell systems analysed. Although it is generally accepted that COX-2 inhibition accounts for the chemopreventive activities of NSAIDs and selective COX-2 inhibitors, also COX-2-independent induction of proapoptotic pathways by these inhibitors has been reported (Elder et al., 1997; Gro¨sch et al., 2001; Waskewich et al., 2002; Jendrossek et al., 2003) . Especially, the observations that much higher COX-2 inhibitor doses are required for apoptosis induction than for suppression of PGE 2 synthesis and that NSAIDs affect cell death irrespective of the COX-2 status provide evidence for their COX-2-independent activities . Also our data are in line with these findings and strongly suggest that the apoptosis-promoting effect of the COX-2 inhibitors used are most likely mediated by mechanisms other than COX-2 suppression alone. With regard to this assumption, we show that TNF-induced COX-2 activity in HeLa H21 cells could be already inhibited by NS-398 concentrations that were 10 000-fold lower compared to those required for the induction of cell death. Furthermore, HeLa H21 cells are completely resistant to apoptosis induced by death receptor ligands such as TNF, anti-CD95 mAb or TRAIL, although COX-2 activity was only induced by TNF. These results not only argue against a predominant role of COX-2 in cell survival of H21 cells, but also suggest that the proapoptotic activity of COX-2 inhibitors such as NS-398 and nimesulide is mediated independently of their COX-2 suppressive function. This assumption is further supported by our observation that also exogenously added PGE 2 could not protect H21 cells from TNF-and NS-398-induced apoptosis. Furthermore, both COX-2 inhibitors, NS-398 and nimesulide, accelerated and enhanced TNF-induced apoptosis even more efficiently in cell lines that do not display any significant COX-2 activity such as HeLa D98 and MCF-7/casp-3/COX-2 cells.
As our data suggesting a COX-2-independent effect in apoptosis induction were obtained in vitro at rather high drug concentrations, a central question certainly is whether comparable effects and mechanisms also occur at inhibitor concentrations that are attainable in humans, that is, o5 mm. Indeed, clincal data on the efficacy of COX-2 inhibitors as antitumor agents suggest that higher doses may be required for antineoplastic than for antiinflammatory effects (Steinbach et al., 2000) . The COX-2 selective inhibitor celecoxib has been recently reported to induce apoptosis in COX-2-deficient human HCT-15 colon carcinoma cells at concentrations of 50-100 mm (Gro¨sch et al., 2001) . Interestingly, despite the requirement of high concentrations in vitro, the authors showed that plasma concentrations of 3-4 mm of celecoxib were sufficient to inhibit tumor progression in a mouse model of HCT-15 cancer xenografts. Furthermore, Song et al. (2002) reported the synthesis of several derivatives of celecoxib. Subsequent structure-activity analyses found no association between the apoptosis-inducing and COX-2-inhibitory effects of the derivatives. This study therefore not only supports the existence of COX-2-independent effects, but also poses new challenges for the development of COX-2 inhibitors with an improved proapoptotic activity.
The most intriguing observation of our study was that the COX-2 inhibitor nimesulide sensitized both HeLa cell lines specifically to the extrinsic, but not to the intrinsic death pathway. Regardless of whether or not death receptor ligands induced COX-2 protein expres- % specific kill Figure 8 Nimesulide has no effect on etoposide-or doxorubicininduced apoptosis. Cell death assessment of HeLa H21 (left panel) and D98 cells (right panel) that were treated for the indicated times with etoposide or doxorubicin in the absence or presence of nimesulide. As a control, cells were also treated with nimesulide alone COX-2 inhibitors enhance death receptor-triggered apoptosis G Totzke et al sion and/or COX-2 activity, nimesulide strongly increased apoptosis mediated by TNF, anti-CD95 mAb or TRAIL, but could not alter sensitivity of the cells to the anticancer drugs etoposide or doxorubicin. This is consistent with recent data demonstrating that NS-398 or celecoxib cotreatment poorly affects anticancer druginduced apoptosis (Davies et al., 2000; Ricchi et al., 2002) as well as with several studies showing that different NSAIDs such as SC-236 and sulindac sulfide can upregulate TRAIL receptor DR5 (He et al., 2002; Huang et al., 2001; Tang et al., 2002) . In contrast, it was recently reported that NS-398 accelerated CD95-induced apoptosis in cholangiocarcinoma cells in a COX-2-dependent manner (Nzeako et al., 2002) . However, no COX-2 activity data were provided and the COX-2-dependent effect of NS-398 was solely based on the observation that addition of PGE 2 prevented apoptosis induced by this inhibitor. Whether this accounts for the apparent discrepancy to our finding is presently unknown, but cell type-specific differences might also play a role. Nevertheless, to our knowledge, this is the first report that specifically compares the effect of COX-2 inhibitors on the extrinsic and intrinsic death pathways. Our observation might be of clinical importance regarding chemotherapeutic treatment of cancer, especially of chemoresistant tumors. The synergistic effect of combining selective COX-2 inhibitors such as NS-398 or nimesulide with death receptor ligands allows the use of lower cytokine doses that otherwise would elicit systemic toxicity or other side effects. Especially, in view of the fact that the apoptosis-promoting activity of the inhibitors is mediated independently of the COX-2 status and, hence, is not restricted to COX-2-expressing carcinomas, this approach might offer a powerful antitumor strategy. It is documented that PGE 2 contributes to the preventive action of COX-2 in apoptosis (Cao and Prescott, 2002) . As we have shown in this study that the apoptosis-promoting activity of COX-2 inhibitors might be mediated independently of COX-2, the questions arise, what are the intracellular targets of these inhibitors and which signal transduction pathways are involved? Several NSAIDs including salicylate and aspirin were shown to inhibit activation of the transcription factor NF-kB that is known to induce the expression of various antiapoptotic proteins (Karin and Lin, 2002) . However, this effect was only observed in HeLa, but not in HepG2 cells, and furthermore, was not induced by ibuprofen, indomethacin or the selective COX-2 inhibitors DFU and nimesulide (Callejas et al., 2000) . In addition, the COX-2 inhibitor SC236 was shown to suppress NF-kB-mediated gene transcription and binding activity in gastric cancer by a mechanism that does not rely on IkBa degradation (Wong et al., 2003) . In our study, we did not obtain evidence that treatment of HeLa cells with nimesulide suppresses NFkB activity (data not shown). Yet it was shown that NS-398 might cause apoptosis by downregulation of antiapoptotic mediators such as Bcl-2 or Mcl-1 (Liu et al., 1998; Lin et al., 2001) . Therefore, it seems likely that drug-and cell type-specific effects on the NF-kB or other stress-induced pathways exist. Also other targets such as the antiapoptotic kinases Akt and ERK-1/-2 or the protein kinase C-b1 were suggested to play a role in apoptosis induction by COX-2 inhibitors (Hsu et al., 2000; Elder et al., 2002; Jiang et al., 2002) . In addition, the proapoptotic enzyme 15-lipoxygenase-l was shown to be upregulated by NS-398 in DLD-1 colon cancer cells (Shureiqi et al., 2000) . Another intriguing possibility that would explain the proapoptotic activity of COX-2 inhibitors might be inhibition of the casein kinases 1 and/or 2. These kinases were shown to render the proapoptotic Bcl-2 member Bid uncleavable by caspase-8, thereby preventing Bid-induced cytochrome c release (Desagher et al., 2001 ). Indeed, it was shown that inhibition of casein kinase 2 enhances anti-CD95-or TRAIL-induced apoptosis (Ravi and Bedi, 2002; Ruzzene et al., 2002) . However, whether any of these pathways are affected by the COX-2 inhibitors in our system is currently under investigation.
In summary, we provide strong evidence that the COX-2 inhibitors NS-398 and nimesulide exert their proapoptotic activities independently of the cellular status of COX-2 and specifically enhance death receptor-induced apoptosis. As COX-2 inhibitors have already entered clinical trials, it will be important to further elucidate their mode of action and the pathways involved, as a combined application of COX-2 inhibitors and death receptor ligands might prove beneficial for the treatment of cancer patients.
Materials and methods
Cells, reagents and antibodies
MCF-7/casp-3 breast carcinoma cells (Ja¨nicke et al., 1998) and the HeLa cell lines H21 and D98 (Ja¨nicke et al., 1994) were cultured in RPMI 1640, supplemented with 10% heatinactivated fetal calf serum, 10 mm glutamine and 50 mg/ml of each streptomycin and penicillin. MMLV reverse transcriptase was from Gibco BRL (Karlsruhe, Germany) and hexamer nucleotides were from Roche (Mannheim, Germany). Taq DNA polymerase and dNTPs were from Eppendorf (Hamburg, Germany). TNF, etoposide, doxorubicin, the monoclonal actin antibody, nimesulide and the protease inhibitors phenylmethylsulfonyl fluoride (PMSF), aprotinin, leupeptin and bacitracin were from Sigma (Deisenhofen, Germany). The COX-2 monoclonal antibody was from Cayman (Ann Arbor, MI, USA) and the horseradish peroxidase-labeled goat antimouse IgG from BioRad (Munich, Germany). Anti-CD95 mAb was from BioCheck (Mu¨nster, Germany) and TRAIL was kindly provided by H Walczak (Heidelberg, Germany). NS-398 and PGE 2 were from Calbiochem (Bad Soden, Germany) and RNAguard was from Amersham Pharmacia (Freiburg, Germany).
Treatment of cells
Unless otherwise indicated, the various death stimuli were used at the following concentrations: TNF (10 ng/ml), anti-CD95 mAb (500 ng/ml), TRAIL (50 ng/ml), etoposide (100 mm) and doxorubicin (1 mg/ml). Cells were incubated with the COX-2 inhibitors NS-398 or nimesulide 1 h prior to stimulation with the different death stimuli. If not otherwise indicated, NS-398 and nimesulide were used at a final concentration of 100 mm.
RNA extraction
Total RNA was extracted with TRI -reagent (Sigma) according to the manufacturer's protocol. RNA quantification was performed spectrophotometrically and the integrity of the RNA was analysed by electrophoresis on a formaldehyde agarose gel stained with ethidium bromide.
Suppression subtractive hybridization
TNF-resistant H21 and TNF-sensitive D98 cells were stimulated with a combination of TNF (100 pg/ml) and cycloheximide (10 mg/ml) for 1 h, and the poly(A) þ RNA was isolated from the total RNA using an oligo(dT)-cellulose column (Amersham Pharmacia). The SSH was performed with the PCR-Select cDNA subtraction kit (Clontech, Palo Alto, CA, USA) as described previously (Stier et al., 2000) .
Reverse transcriptase-polymerase chain reaction
To confirm the differential expression of the COX-2 gene and to perform semiquantitative mRNA expression studies, HeLa cells were stimulated with TNF, etoposide, doxorubicin, anti-CD95 mAb or TRAIL in a time-dependent manner. The 5 0 (5 0 -GTATGAGTGTGGGATTTGAC-3 0 ) and 3
0 ) primers for the amplification of a COX-2 cDNA fragment of 302 bp were synthesized commercially (Gibco BRL). For standardization purposes, each RT sample was subjected to PCR for glyceraldehyde-3-phosphate dehydrogenase (5 0 primer: 5 0 -GCCAAAAGGGT-CATCATCTC-3 0 ; 3 0 primer: 5 0 -GTAGAGGCAGGGAT-GATGTTC-3 0 ). RT and PCR were performed as described previously (Ko et al., 1995) . A total volume of 20 ml of each PCR reaction was loaded on an ethidium bromide-stained agarose gel. The fX-174-RF DNA HaeIII digest was used as a marker.
SDS-PAGE and Western blotting
Cell pellets were resuspended in lysis buffer (150 mm NaCl, 50 mm Tris, pH 7.4, 1 mm DTT, 1% NP-40) in the presence of 1 mm PMSF and 10 mg/ml of each aprotinin, leupeptin and bacitracin and incubated for 30 min on ice. After centrifugation at 13 000 r.p.m. for 30 min at 41C, protein concentrations of the supernatants were determined with the BioRad protein assay (BioRad, Munich, Germany). Equal amounts of the proteins were separated in an 8% SDS-polyacrylamide gel and transferred electrophoretically to a polyvinylidene difluoride membrane (Amersham Pharmacia). The membrane was blocked with 5% defatted milk powder in TBS/0.1% Tween for 2 h and incubated overnight at 41C with the monoclonal COX-2 and actin antibodies (each diluted 1 : 1000) in the blocking buffer. Following incubation for 1 h with the secondary antibody (horseradish peroxidase-labeled goat anti-mouse IgG, dilution 1 : 30 000) in TBS/0.1% Tween/5% milk powder, the proteins were visualized by enhanced chemiluminescent staining using ECL reagents (Amersham Pharmacia).
Measurement of COX-2 activity
Cells (10 5 /well) were seeded in duplicates into 24-well plates and grown overnight in culture medium. Cells were either stimulated with the indicated death stimuli alone or in combination with NS-398 for 3, 6 and 12 h. For determination of a dose-response, HeLa H21 cells were exposed to NS-398 at concentrations ranging from 0.001 to 100 mm prior to the addition of TNF. The supernatants were collected and the PGE 2 concentration was determined by an enzymeimmunoassay (EIA) according to the manufacturer's protocol (Amersham Pharmacia).
Cytotoxicity assay
The standard crystal violet assay was employed as described (Ja¨nicke et al., 1994) . Briefly, cells (2 Â 10 5 /ml) were seeded into 96-well microtiter plates in 100 ml culture medium. Cells were incubated with various concentrations of the indicated death stimuli in the presence or absence of nimesulide or NS-398. After incubation for various times at 371C, viable cells were stained with 20% methanol containing 0.5% crystal violet and solubilized in 33% acetic acid. The absorbance was measured at OD 590 nm (A 590 ). The percentage of specific kill is defined as 100À(A 590 of test well Â 100/A 590 of untreated well). Each experiment was performed independently at least two times in triplicates. Values are given as means7s.d.
Construction of the COX-2 expression vector and stable transfection
The expression plasmid pcDNA3/hCOX2, kindly provided by Dr Thomas E Eling (North Carolina, USA), served as a PCR template to generate a COX-2 cDNA containing the BamHI/ XhoI site for subcloning into a Myc-His-tagged expression plasmid (pcDNA4/His-Myc; Invitrogen, Groningen, The Netherlands). The correct sequence of the COX-2 cDNA was confirmed by sequence analysis. MCF-7/casp-3 cells were stably transfected either with the generated COX-2 expression plasmid (pcDNA4/His-Myc/COX-2) or with the empty control vector using FuGENE according to the manufacturer's protocol (Roche, Mannheim, Germany). Positive clones were obtained by zeocin selection (500 mg/ml) and the overexpression of COX-2 was confirmed by Western blot analysis.
